Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer

Published:2020-12 Issue:23 Volume:8 Page:1611-1611
ISSN:2305-5839
Container-title:Annals of Translational Medicine
language:
Short-container-title:Ann Transl Med

Author:

Borcoman Edith,Le Tourneau Christophe

Publisher

AME Publishing Company

Subject

General Medicine

Link

http://atm.amegroups.com/article/download/46503/pdf

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bridging the Gap: Immune Checkpoint Inhibitor as an Option in the Management of Advanced and Recurrent Cervical Cancer in Sub-Saharan Africa;Cureus;2024-09-10

2. PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer;Future Oncology;2024-06-03

3. Combination pembrolizumab and lenvatinib in metastatic mismatch repair deficient adenocarcinoma of Mullerian origin: A case report;Current Problems in Cancer: Case Reports;2024-06

4. Case report: A case of recurrent cervical cancer with bronchial and esophageal metastases presenting with hemoptysis and dysphagia;Frontiers in Oncology;2024-04-19

5. Comparison of programmed death‐ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer;Cancer Reports;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP